Across TCGA pan-cancer cohorts, MIR6780A RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR6780A’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR6780A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR6780A is over-expressed in tumor.
STAD and COAD are the cancer types where MIR6780A tumor–normal differential expression is most reproducible.